Filtered By:
Cancer: Breast Cancer
Education: Study
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 411 results found since Jan 2013.
Baseline cardiovascular comorbidities, and the influence on cancer treatment decision-making in women with breast cancer
CONCLUSION: While recent guidelines recommend routine assessment of cardiovascular comorbidities in cancer patients prior to initiation of anticancer therapies, this study highlights the prevailing gap in knowledge on how such data may be used to optimise cancer treatment decision-making.PMID:34824616 | PMC:PMC8580595 | DOI:10.3332/ecancer.2021.1293
Source: Ecancermedicalscience - November 26, 2021 Category: Cancer & Oncology Authors: Shridevi Subramaniam Yek-Ching Kong Hafizah Zaharah Cuno S P M Uiterwaal Andrea Richard Nur Aishah Taib Azura Deniel Kok-Han Chee Ros Suzanna Bustamam Mee-Hoong See Alan Fong Cheng-Har Yip Nirmala Bhoo-Pathy Source Type: research
Is stroke incidence increased in survivors of adult cancers? A systematic review and meta-analysis
ConclusionsStroke incidence is significantly increased after diagnosis of certain cancers.Implications for Cancer SurvivorsCardiovascular risk should be assessed during cancer survivorship care, with attention to modifying shared cancer/cardiovascular risk factors.
Source: Journal of Cancer Survivorship - November 5, 2021 Category: Cancer & Oncology Source Type: research
Comparison of impedance cardiography and cardiac magnetic resonance imaging for the evaluation of
cardiac function in early-stage breast cancer patients
Objective. Breast cancer treatment can negatively impact cardiac function in some breast cancer
patients. Current methods (MUGA, echocardiography) used in clinical practice to detect abnormal
cardiac changes as a result of treatment suffer from important limitations. Use of alternative
techniques that would offer safe, inexpensive and non-invasive cardiac function assessment in this
population would be highly advantageous. The aim of this study was to examine the agreement between
impedance cardiography (ICG) and cardiac magnetic resonance imaging (CMR) in quantifying stroke
volume (SV), cardiac output (CO) and end-d...
Source: Physiological Measurement - November 3, 2021 Category: Physiology Authors: Erifyli Piastopoulou, Parvaiz Ali, Gianfilippo Bertelli, Martyn Heatley, Maung Moe, Chandramohan Murugesan, Gareth Stratton and Michael Lewis Source Type: research
Bringing WISDOM to Breast Cancer Care
Dr. Laura Esserman answers the door of her bright yellow Victorian home in San Francisco’s Ashbury neighborhood with a phone at her ear. She’s wrapping up one of several meetings that day with her research team at University of California, San Francisco, where she heads the Carol Franc Buck Breast Care Center. She motions me in and reseats herself at a makeshift home office desk in her living room, sandwiched between a grand piano and set of enormous windows overlooking her front yard’s flower garden. It’s her remote base of operations when she’s not seeing patients or operating at the hospita...
Source: TIME: Health - October 22, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Source Type: news
Causes and Consequences of Polycystic Ovary Syndrome: Insights from Mendelian Randomization
CONCLUSIONS: The accumulation of genome-wide association studies in PCOS has enabled multiple MR analyses identifying factors that may cause PCOS or be caused by PCOS. This knowledge will be critical to future development of measures to prevent PCOS in girls at risk as well as prevent complications in those who have PCOS.PMID:34669940 | DOI:10.1210/clinem/dgab757
Source: The Journal of Clinical Endocrinology and Metabolism - October 20, 2021 Category: Endocrinology Authors: Tiantian Zhu Mark O Goodarzi Source Type: research
ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also suppor...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice
AbstractBACKGROUNDMenopausal symptoms can be very distressing and considerably affect a woman ’s personal and social life. It is becoming more and more evident that leaving bothersome symptoms untreated in midlife may lead to altered quality of life, reduced work productivity and, possibly, overall impaired health. Hormone therapy (HT) for the relief of menopausal symptoms has been the obj ect of much controversy over the past two decades. At the beginning of the century, a shadow was cast on the use of HT owing to the concern for cardiovascular and cerebrovascular risks, and breast cancer, arising following publication ...
Source: Human Reproduction Update - August 25, 2021 Category: OBGYN Source Type: research
Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study
CONCLUSION: Our results indicate an increased risk for ischemic heart disease and arrhythmia in patients treated for more than four years with AIs. This should be considered in the risk-benefit assessment concerning endocrine therapy.PMID:34265496 | DOI:10.1016/j.breast.2021.07.004
Source: Breast - July 15, 2021 Category: Cancer & Oncology Authors: Maria Sund Miguel Garcia-Argibay Hans Garmo Johan Ahlgren Anna-Karin Wennstig Irma Fredriksson Henrik Lindman Antonis Valachis Source Type: research
